Use of hormone replacement therapy in the Hong Kong public health sector after the Women's Health Initiative trial

Maturitas

Volumn 52, Issue 3-4, 2005, Pages 277-285

  Leung, K Y ^a   Ling, Matina ^a   Tang, G W K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hong Kong; Hormone replacement therapy; Menopause; Women

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; RALOXIFENE; TIBOLONE;

ARTICLE; DRUG RESEARCH; DRUG UTILIZATION; HONG KONG; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INFORMATION RETRIEVAL; MENOPAUSAL SYNDROME; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; PUBLICATION;

AGE FACTORS; AGED, 80 AND OVER; DRUG UTILIZATION; ESTROGENS; FEMALE; HONG KONG; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; MIDDLE AGED; POSTOPERATIVE PERIOD; PRESCRIPTIONS, DRUG; PROGESTINS; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EQUIDAE;

EID: 27644456345     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.04.008     Document Type: Article

References (26)

1. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
2. Million Women Study Collaborators Breast cancer and hormone replacement therapy in the Million Women Study Lancet 362 2003 419 427
3. North American Menopause Society Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of the North American Menopause Society Menopause 10 2003 6 12
4. Australian Drug Evaluation Committee. ADEC statement on use of hormone replacement therapy, available at http://www.tga.gov.au/docs/html/hrtadec.htm [accessed October 19, 2003].
5. British Menopause Society. Managing the menopause. British Menopause Society Council Consensus statement on hormone replacement therapy, available at http://www.the-bms.org/conses_stat.htm [accessed October 19, 2003].
6. American College of Obstetricians and Gynecologists. Statement of The American College of Obstetricians and Gynecologists on hormone therapy for the prevention and treatment of postmenopausal osteoporosis for the FDA Endocrinologic and Metabolic Drugs Advisory Committee, available at http://www.acog.org/from_home/publications/press_releases/nr10-07-03.cfm [accessed October 19, 2003].
7. A.L. Hersh, M.L. Stefanick, and R.S. Stafford National use of postmenopausal hormone therapy JAMA 291 2004 47 53
8. D.S. Buist, K.M. Newton, and D.L. Miglioretti Hormone therapy prescribing patterns in the United States Obstet Gynecol 104 2004 1042 1050
9. B. Lawton, S. Rose, D. McLeod, and A. Dowell Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users Br Med J 327 2003 845 846
10. A.H. Maclennan, A.W. Taylor, and D.H. Wilson Hormone therapy use after the Women's Health Initiative Climacteric 7 2004 138 142
11. K.Y. Leung, M. Ling, and G.W.K. Tang Continuation rate of hormone replacement therapy in Hong Kong public health sector Maturitas 49 2004 338 344
12. J.S. Haas, C.P. Kaplan, E.P. Gerstenberger, and K. Kerlikowske Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results Ann Intern Med 140 2004 184 188
13. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
14. D. Grady, D. Herrington, V. Bittner HERS Research Group Cardiovascular disease outcomes during 6.8 years of hormone therapy JAMA 288 2002 49 57
15. G. Ena, and S. Rozenberg Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study Hum Reprod 18 2003 2245 2248
16. S.R. Majumdar, T.S. Inui, J.H. Gurwitz, M.W. Gillman, T.J. McLaughlin, and S.B. Soumerai Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction J Gen Intern Med 16 2001 351 359
17. M. Maclure, C. Dormuth, and T. Nauman Influence of educational interventions and adverse news about calcium channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia Lancet 352 1998 943 948
18. J.E. Blumel, C. Castelo-Branco, and P.A. Chedraui Patients' and clinicians' attitudes after the Women's Health Initiative study Menopause 11 2004 57 61
19. T. Kocjan, and G.M. Prelevic Hormone replacement therapy update: who should we be prescribing this to now? Curr Opin Obstet Gynecol 15 2003 459 464
20. North American Menopause Society Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society Menopause 11 2004 11 33
21. P. Amato, and D.M. Marcus Review of alternative therapies for treatment of menopausal symptoms Climacteric 6 2003 278 284
22. A.C. Bagur, and C.A. Mautalen Risk for developing osteoporosis in untreated premature menopause Calcif Tissue Int 51 1992 4 7
23. J.N. Anasti, S.N. Kalantaridou, L.M. Kimzey, R.A. Defensor, and L.M. Nelson Bone loss in young women with karyotypically normal spontaneous premature ovarian failure Obstet Gynecol 9 1998 12 15
24. L.Y. Chan, and P.M. Yuen Influence of the Women's Health Initiative trial on the practice of prophylactic oophorectomy and the prescription of estrogen therapy Fertil Steril 81 2004 1699 1700
25. G.L. Anderson, M. Limacher, A.R. Assaf Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
26. D. Pilon Estrogen replacement therapy: determinants of persistence with treatment Obstet Gynecol 97 2001 97 100